Overview

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the administration of risperidone alone or in combination with mifepristone in healthy adult male volunteers to determine the average change in absolute weight at Day 28 compared to baseline.
Phase:
Phase 2
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Mifepristone
Risperidone